MedTrace Logo

Combined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy

NCT06653400 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-31

No results posted yet for this study

Summary

A randomized double-blind placebo controlled trial comparing the effect of a combined ketorolac and lidocaine paracervical block with a standard lidocaine paracervical block on procedure related pain with office hysteroscopies.

Conditions

  • Abnormal Uterine Bleeding
  • Analgesia
  • Paracervical Block

Interventions

PROCEDURE

paracervical block

paracervical block with office hysteroscopy

DRUG

Lidocaine

Dosage: 20 mL of 1% lidocaine

DRUG

ketorolac

Dosage: 2 mL (30 mg) of ketorolac

Sponsors & Collaborators

Principal Investigators

  • Charles Ascher-Walsh, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-27
Primary Completion
2026-09-01
Completion
2026-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06653400 on ClinicalTrials.gov